Headache medicine specialist Rebecca C. Burch, MD, joins us to talk about triptan use in patients with cardiovascular risk factors. Listen in as they clear up confusion about which patients should avoid triptans due to cardiovascular concerns. You’ll also hear practical advice from panelists on TRC’s Editorial Advisory Board: Anthony A. Donato, Jr., MD, MHPE, Associate Program Director, Internal Medicine from the Reading Health System, and Professor of Medicine at the Sidney Kimmel Medical College at Thomas Jefferson University Steven E. Nissen, MD, MACC, the Chief Academic Officer at the Heart and Vascular Institute and the Lewis and Patricia Dickey Chair in Cardiovascular Medicine Professor of Medicine at the Cleveland Clinic Lerner School of Medicine at Case Western Reserve University Joseph Scherger, MD, MPH, Family Physician, Primary Care 365, Eisenhower Health Craig D. Williams, PharmD, FNLA, BCPS, Clinical Professor, Department of Pharmacy Practice at the Oregon Health and Science University For the purposes of disclosure, Dr. Steven Nissen reports a relevant financial relationship with AbbVie, Amgen, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Esperion, Medtronic, Novartis, Pfizer, Silence Therapeutics (grants/research support). The other speakers have nothing to disclose. All relevant financial relationships have been mitigated. Pharmacist’s Letter offers CE credit for this podcast. Log in to your Pharmacist’s Letter account and look for the title of this podcast in the list of available CE courses. Claim Credit 🗪 Send us Fan Mail Email us: ContactUs@trchealthcare.com. The content of this podcast is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Medication Talk is a production of TRC Healthcare. Find the show on YouTube by searching for ‘TRC Healthcare’ or clicking here. Learn more about our product offerings at trchealthcare.com.
Audio and video play straight from the show's own hosting. PodSubs stores and serves no media.
Transcript
From the show. Tap a time to play from there.
NarratorWelcome to Medication Talk, the official podcast of TRC Healthcare, Homopharmacist Letter, Prescribers Letter, RX Advanced, and the most trusted clinical resources. On today's episode, we'll be listening in as our expert panel clears up confusion about which patients should avoid tryptins due to cardiovascular concerns. Our guest today is headache medicine specialist, Dr. Rebecca Birch. You'll also hear practical advice from panelists on TRC's Editorial Advisory Board, Dr. Anthony Donato from the Reading Health System, Dr. Stephen Nitson from the Cleveland Clinic, Dr.
NarratorJoseph Schurger from Primary Care 365 and Eisenhower Health, and Dr. Craig Williams from the Oregon Health and Science University. This podcast is an extract from TRC's Emerging Recommendations panel webinar. Each month, experts and frontline providers discuss current medication therapy topics and practical recommendations to include in TRC's letter articles. The full webinar originally aired on November 14, 2022.
CE NarratorAnd now, the CE information.
NarratorPharmacist Letter offers CE credit for this podcast. Please log into your Pharmacist Letter account and look for the title of this podcast in the list of available CE courses. For the purpose of disclosure, Dr. Steven Nitson reports a relevant financial relationship by receiving grants or research support from AB, Amgid, AstraZeneca, Bristol Myers Squib, Eli Lilly, Asphrion, Medtronic, Novartis, Pfizer, and Silence Therapeutics. The other speakers you'll hear have nothing to disclose. All relevant financial relationships have been mitigated.
NarratorNow, let's join TRC editor, Dr. Lauria Dickerson, and start our discussion.
Lori DickersonAnd we're talking about this now because we're getting questions about which patients should avoid tryptans due to cardiovascular concerns. And so, Rebecca, to get us started, can you briefly review for us what the package labeling does say about cardiovascular risks with tryptans?
Rebecca C. BurchYeah, I'm happy to. So currently, tryptan package labeling says that tryptans should be avoided in patients with a history of coronary artery disease or coronary artery vasospasm, Wolf Parkinson-White syndrome, cardiac accessory conduction pathway disorders, history of stroke, TIA, or hemiplegic, or what used to be called uh basilar migraine is now migraine with brainstem aura, as well as peripheral vascular disease. And this came about because there were some uh studies in animals prior to FDA approval of sumatryptan that showed uh vasoconstriction.
Rebecca C. BurchAnd this was also uh shown in some early human studies as well. So that's how it came to be on the package.
Lori DickersonSo historically, this stems from some of these cases that you've mentioned, and the labeling was tryptans, you know, came out many, many years ago in the 1990s when maybe there were less rigorous requirements for including in labeling. So do you can you just comment a little bit more about that, Rebecca, and how you think uh some of this sort of maybe looser data ended up there?
Rebecca C. BurchWell, I do think that prior to um knowing that this was uh a major issue, some patients with cardiovascular disease may have put through into tryptan trials. Um, I do think that regardless of cardiac risk, this is still an issue for um for some patients. It can be a little bit idiosyncratic and that um you know has been has been borne out um in case studies after uh approval.
Lori DickersonGreat. Well, I want us to dig some more into that. And Steve, I guess I wanted to hear from you too, as a cardiologist, uh is you know, your um historical perspective on the safety of tryptans in terms of cardiovascular risk.
Steven E. NissenI think some of this is historical. You know, going back to the days when ergot preparations were used for migraine, and it was kind of assumed that tryptans work by a same similar mechanism. I'm not sure if they do or do not. It's it's extraordinary that something this important has not really been rigorously tested in large randomized controlled trials. I mean, how many millions of people have taken these drugs over the years and we still don't have definitive evidence?
Steven E. NissenI've looked at the literature, um, I'm not uh impressed with the quality of the evidence one way or another. And so we're left with this theoretical issue without a lot of very good evidence that that's actually what we see in patients.
Lori DickersonAnd so, Rebecca, just to get us all on the same page too, can you just speak to the mechanism of ergots versus the mechanism of tryptans and sort of how those two might have been intertwined in terms of risk?
Rebecca C. BurchYeah, so there was a historical thinking that tryptans primarily worked through a mechanism of vasoconstriction, similar to ergots, or the thinking around how ergots may have worked as well. And as we know more about the pathophysiology of migraine, the thinking has really changed from it primarily being a vascular disorder to primarily being a neuronal disorder or a neurovascular disorder. And with that, our understanding of tryptan mechanism of action has changed to affecting release of neuropeptides, nosusceptive neuropeptides, and um, you know, things like CGRP, although that's not the only one, and really stopping uh an attack at the neuronal level.
Lori DickersonAnd Steve, to come back to um, you know, the risk of myocardial infarction specifically, you know, I think originally the thought was that MIs were caused by vasospasm, and that thinking has changed. And so you can you comment a little bit about that change?
Steven E. NissenWell, that was hotly debated 50 years ago, and that debate was uh, you know, is no longer you know very commonly discussed. But there is one statement in your article that's not quite right.
Lori DickersonOkay.
Steven E. NissenIt says now we know that most CV events are from plaque rupture and thrombosis. Actually, it's about two-thirds of MIs are from plaque rupture and thrombosis. About one-third are due to plaque erosion, which is a little bit of a different phenomenon, but there's really not a lot of evidence that they're due to vasoconstriction. And so this whole hypothesis around why tryptans might cause cardiovascular events, it kind of blows up in the contemporary uh era.
Lori DickersonSo, Steve, how would you adjust this line to include plaque erosion? Uh, is there a sort of a broader term that we could use?
Steven E. NissenI would say that you know most cardiovascular events are not due to coronary vasospasm.
Lori DickersonYeah, okay.
Steven E. NissenIn fact, vasospasm is actually just so-called prince metal's variant angina, is practically completely disappeared for other reasons uh from uh contemporary medicine. It's no longer even diagnosis that we make.
Lori DickersonOkay. I was going to ask you about Prince Metal because I wondered, uh, you know, certainly was something that we learned about years ago, but don't talk about today. So all right. Well, that's very helpful. Any um other comments, Craig? Did you have anything to add to this discussion? I thought they're all great.
Craig WilliamsYeah, I know they're all great points. I think the uh I'll echo Steve's earlier point about these really are kind of derivatives of the ergots, and I use the analogy of we still, you know, kind of paint met foreman as a sunfn foreman and carry over adverse effects from a parent drug that don't apply to it. I think that's kind of happened here. And I think it's maybe worth putting a line in about that for readers because we're also used to this warning for the last few decades, you know, it's gonna take a little bit to get some people beyond this idea that I don't have to worry about. But I think the point is that it was painted with the adverse effects of ergots and doses of ergots back in the 70s and 80s were were high, and appropriate doses of of tryptans don't have the same vascular effects systemically.
Lori DickersonOkay, very helpful, very helpful. Now, um, if we just get back to um the phrase that we have here about the thinking is changing on how tryptans work. You know, Rebecca, in some of our early discussions with you, um, you know, you were talking about how this topic topic is difficult because we're in such a low evidence zone, and um, you know, about the gray area that we have here. And can you can you just comment a little bit more on that and um how it is hard to prove a negative?
Rebecca C. BurchYeah, I I think there's two issues. So one thing I want to say about the discussion around the mechanism of um MI in patients who've taken tryptans is not the necessarily that vasospasm is thought to be the only mechanism, but the reason that we're concerned about patients with other um cardiovascular risk factors is that if there's a partially blocked artery and then there's a vasospasm on top of that, that that may put the patient at risk, not that it's vasospasm by itself.
Rebecca C. BurchAnd I also want to point out that there have been numerous studies showing that tryptans by themselves are associated with um coronary events in individual patients. Um, and that there are case studies still coming out. There was one published last year. Um, so it's not um that this never happens. I think the question is how much do we have to worry about it? How likely is this risk?
Rebecca C. BurchAnd um, you know, is there a way we can predict? And I think one of the really difficult things, and I, you know, this this was mentioned earlier, is that this is a really important question, and the evidence we have is really challenging because the epidemiology studies that we have show that tryptans are, if anything, um they look protective against uh cardiovascular events. But when you do a deeper dive into the um studies, what you actually find is that's just because these tryptans are just not prescribed to people with cardiovascular risk factors.
Rebecca C. BurchAnd so what all of these studies actually show is that prescribers are doing a really great job of following the package labeling.
Steven E. NissenI I I would just maybe push back a little bit and just say that you know, the the study I tried to look before this meeting at uh at the studies and they're just of terrible quality. And so it's hard to make a policy uh decision. For FDA, it's really easy. Yeah, you know, the the onus is on somebody else to prove that their labeling is wrong, and no one's gone after doing that, but I really don't find very much compelling evidence.
Steven E. NissenYes, people that have migraine sometimes have cardiovascular events, people that take trypt cans has sometimes have events. That doesn't mean the trypt cans cause that event. And so I'm looking for solid evidence and I'm just not finding.
Lori DickersonAnd so we you make the point, Rebecca, you know, too that uh prescribers are doing a good job of following package labeling, but we do we did find, and I think we have it in our article too, that about 15% of patients who get a trap trip down have at least one cardiovascular contraindication or multiple cardiovascular risk factors. So some of those people have boats slipped through the cracks. Um, and so, gosh, so many people want us to put a number needed to harm in here. You know, what is the number needed to harm? And of course, we know that we don't have a number needed to harm because we don't have you know good RCT data to help us uh calculate that.
Lori DickersonSo the phrasing that we have here in the next slide is that atryptans are rarely associated with adverse cardiovascular events. And so I'm wondering um what everybody thinks about this phrase and um if we should say it differently, if we should say more, or so Rebecca, what are your thoughts here?
Rebecca C. BurchYeah, I mean, I think one of the things I was thinking about before today's call is um what is the rationale for wanting to be more liberal about um tryptan prescribing? And you know, that's particularly the case now that we have alternatives that are not thought to cause vasoconstriction and are, you know, pretty effective. And I I just tend to err a little bit on this side of caution um simply because in the absence of good evidence for safety, I don't see a reason to change to put somebody at potential risk.
Rebecca C. BurchAnd I think there's always going to be individual prescriber variation and comfort levels and you know approach to decision making around that. I feel I feel comfortable saying that you know the the risk is low, but I also think it's important to say that we don't have a lot of evidence about safety in people with, you know, a large number of cardiovascular risk.
Lori DickersonYou know, Craig, I wanted to hear from you too, because you had some good thoughts about sort of why we're rethinking this question now, which has to do with some of the newer medications that we have. So can you share your your background, your thoughts on that?
Craig WilliamsWell, I just think the in the last decade, I mean, I'm old enough to remember all these debates from the 90s and similar Steve did some preparation for the meeting. And yeah, when you get back into that data, it was ex vivo and in vitro and interesting. And what these drugs clearly can do, like ergots, is slightly raise uh blood pressure. Um, but so many things raise blood, I mean having a migraine raises blood pressure, and exercise raises blood pressure. And it was it was hard for me to find evidence to convince me that we should be worried about this, other than because we were worried about this, many of these patients were not included in the trials.
Craig WilliamsThey got tryptans approved. So now we're trying to play catch-up, and as Rebecca said, it's very hard to prove a negative to prove these are safe. And as Steve said it's easy for the FDA to say there's a theoretic concern and these people weren't in the trials, so we're gonna exclude them. But in the real world, I think if we're stewards of the healthcare system, I mean for about a third of patients who take tryptans, they're really, really effective drugs at a small fraction of the cost from the regents that Rebecca is referring to. So I just I don't see concerns to not at least try it in those patients, knowing that even if it does raise blood pressure slightly for a short time, I'm just not sure that's a valid concern for long-term carbastes in the patients.
Steven E. NissenYeah, you know, ADHD drugs raise raise blood pressure, but no, nobody seems to be afraid of giving them chronically. And, you know, uh these are not given necessarily uh chronically, is that correct? Correct. Correct, these are intermittently, yeah, yeah. Um I guess the the I also would echo what Craig said about the cost-effectiveness issue. You know, not everybody can afford the latest and greatest uh therapies. So if a time-honored therapy is effective and we found out that many of them are, then you know, we need to lift the veil off of it and and allow people to use it.
Steven E. NissenI I think somebody, you know, maybe the NIH, you know, needs to fund a decent sized trial where people are where we study this effect and and find out if there really is anything to it or not.
Craig WilliamsYeah, I do think too, Laura. I think if uh you know the cynic community say the companies making these newer drugs, if they thought they had a case to make, they probably would do that. I mean, it'd be fantastic if they could prove they were safer and get trip chans out of everyone's hands. And I don't see that coming.
Lori DickersonWell, we we will talk about that. This is you know, such a great discussion. Uh, and this is why we wanted to pick this topic up because there's you know sort of this sort of new churning of um the grayness um in in this risk. And uh appreciate all the sort of epidemiologic background that you've given Rebecca. And you know, one other point that we um included in the article that we thought was interesting is that other countries have have their tripped hands, quote, over the counter.
Lori DickersonUh now those are behind the counter that the patient has to ask the pharmacist for, but they and certainly the pharmacist would have to ask some questions, but they do not have to be prescribed. And so that's just sort of an interesting tidbit, too, that um, you know, sort of contrasts the difference uh in in the US labeling. And so just wondering if that's something that's commonly discussed, Rebecca, in in your literature and in the neurology headache literature.
Rebecca C. BurchYeah, uh, you know, and again, I I don't think many headache specialists are terribly worried about, you know, a transient increase in in blood pressure either. So I think we're all you know in agreement on on that point. Um, yeah, so tryptans are behind the counter in the UK and Germany, and I believe just earlier this year they went in that direction for Australia as well. There are some South American countries also that follow that, but it doesn't mean over the counter in the same way that you can, you know, walk in and grab an ibuprofen um, you know, off a shelf.
Rebecca C. BurchYou you have to go talk to the pharmacist. They, at least in the UK, require that you check off um some questions saying you don't have cardiovascular disease. So there is still some um, you know, screening that happens. And I agree that in the grand scheme of things, it does point to these, you know, being safe and well tolerated.
Lori DickersonOkay, well, I just wanted to give that sort of more global perspective. And so, Rebecca, let's actually uh, you know, turn around and talk about what we're going to do with all this information because it is, of course, nice to know that um there's gray out there, but the package labeling still says what it says, and we still have patients who need treatment. And so um, the first statement we have about what to do is uh about evaluating cardiovascular risk factors in patients with migraine and uh treat those risk factors if needed.
Lori DickersonAnd so um just curious from your perspective, we have an audience question, Rebecca, coming in, wondering if there is a specific risk estimator that we should use to evaluate whether or not uh a patient should use a tryptan or not, or is this just your clinical decision making and your gestalt?
Rebecca C. BurchThere is no specific risk uh calculator that had specialists use to make this decision. So we really just look at um, you know, things like framing ham, um, you know, risk score and uh, you know, other cardiovascular risk factors. The list that you have up there for things to ask is good, I would add diabetes to it. Okay.
Lori DickersonAs an additional thing to consider. And so, Craig, I think you had some comments about this too, and you were wondering about um how we would estimate risk. Did you have any thoughts on on this?
Craig WilliamsNo, I mean I think the global we've had many debates about the you know, the global risk calculator, but I I think that's still what we use it in practice. This would be another good reason to use it. Uh, I think clinicians probably still underutilize that and and don't think about the combined risk of factors in patients as often as they should. So have any better.
Steven E. NissenBy the way, this would be a reasonable case for shared decision making. I think you know, if you can present a patient with their uh their risk estimate based upon whatever risk formula you want to use, and then discuss it with them. And there may be patients that that really are are finding these drugs to be highly effective, and you know, they certainly don't want to stop them, and it's a chance for some shared decision making.
Lori DickersonGood point, Stephen. I skipped over that line. We do have that uh further up in the article that says help patients put the risk of tryptans in perspective. And so I appreciate that you brought that up. And so if we talk about our um patients with um uh um a low cardiovascular risk first, that end of the spectrum, uh, we make the statement to continue to consider tryptans for patients at low cardiovascular risk, such as those with blood pressure at goal or an aestatin for high cholesterol. And so, Rebecca, I'm assuming that you will agree with this statement. Yes, absolutely.
Lori DickersonOkay, and Joe, I'm just curious as a primary care doc, as a family doc, um how do you feel about using tryptans in patients with low cardiovascular risk like this? If you were treating, if you were giving them an uh an abortive agent for their migraine.
Joseph SchergerI'm uh completely comfortable and I do it on a regular basis. So uh I I don't worry about uh people with low cardiovascular risk. You know, sometimes with advanced age, it makes me a little more nervous, but uh you know, so far uh, you know, those are not people that are getting migraines near as common-aged people.
Lori DickersonYou know, I'm glad you brought that up. We do have a line further down um where we say it's okay if an older patient on BP meds opts for a tryptan. Um and so that you've now that you've brought up age, Rebecca, do you would you agree with that statement, sort of thinking about the cumulative risk of age and hypertension, treated hypertension?
Rebecca C. BurchI don't think of age by its itself necessarily as a risk factor. I think that as people get older, they tend to accumulate other cardiovascular risk factors. And so this is a a place where again that kind of holistic um you know perception and of of risk comes into play. And but I I had you know have plenty of patients who are older and on tryptans uh you know and they don't have other contraindications and I don't have any issue with that at all.
Rebecca C. BurchOkay.
Lori DickersonVery good. And Andy I wanted to ask you too we are using this piece in our hospital pharmacist letter and uh you know I I think uh we're in general tryptans are not used in the hospital and we say for acute treatment continue to use things like IV pro chlorperazine or metaclochromide. Is that consistent with your practice Andy?
Anthony A. DonatoThat is um I do use tryptans for people that are in for something else and tryptans always work for them if they if they get them but I'm I'm not necessarily introducing them to people that that are de novo.
Lori DickersonOkay great point and that might be a good little tidbit for us to include also in this piece with that pearl. Thank you so much for that. Now Rebecca um we do state that there's no proof that certain tryptans, dosage forms or lower doses pose less cardiovascular risk. Would you agree with that statement? Is one tryptan safer than another?
Rebecca C. BurchYeah I looked through the literature and I did not see any evidence that any one tryptan has been compared to any other in this regard so I I agree with that.
Lori DickersonOkay. So let's look at the other end of the spectrum now high cardiovascular risk. Rebecca we say to avoid tryptons in patients at the highest cardiovascular risk such as those with a prior MI stroke or subarachnoid hemorrhage. I think those are pretty clear contraindications would you agree with that? Yes. And the question that comes up is what does prior MI mean? Is that ever? Is it recent?
Rebecca C. BurchI think it's meant to be ever but there I mentally carve out a patient who has had angioplasty and a subsequent clean calf um obviously I'd be interested in you know hearing other opinions about that what um Craig thinks.
Lori DickersonYeah what do you think Craig and Steve on on that sort of prior MI definition.
Craig WilliamsYeah I mean if you can find that pay well let's Steve if you can find that patient with an otherwise clean calf after uh that'd be an uncommon patient but yeah.
Steven E. NissenYou know the the thing I'm struggling with here is that we say high high risk but we're really trying to make this recommendation in the absence of solid data. So we can pick any threshold of risk that we want. I did want to mention something about this issue of age. If you look at the pool cohort equations once you get to be a certain age you are you are high risk by definition.
Lori DickersonIt's all age driven and so uh I don't know that while age may be irrelevant to the practitioner it isn't irrelevant to the guideline writers nor to the risk calculators risk estimators so so you've really got a problem here in that everybody who's older is going to have a high cardiovascular just about and so let's talk about those in-between people Rebecca and we say for everyone in between discuss the pros and cons and think of cardiovascular risks as additive and so I think that's um that's wording that you share with us when you're thinking about these folks that you know maybe age and diabetes and and uh uncontrolled hypertension for example would would add up and uh tip you towards a different agent and so uh would you agree with sort of that phrasing that we have there if you go to that uh next set slide I think we have an example of um you know when some case a case where we might choose to do something different.
Lori DickersonSo could you comment on the cardiovascular multiple cardiovascular risks? I'm sorry I get a little ahead of myself there Rebecca.
Rebecca C. BurchYeah I think that wording um you know I I I agree with with what I I guess had suggested before um I really like the suggestion for shared decision making because I do think that these are always individualized decisions. It depends on what the risk factors are, how much they're felt to contribute, whether they're modifiable in any way, whether other treatments are you know accessible as the point was made, whether they work um how often you know someone needs treatment, how severe the headaches are and how they're impacting quality of life you know there's so many factors and I think it's again we're in a gray area and I think gray areas are where shared decision making and individualized treatment decisions really are extremely important.
Rebecca C. BurchNot that they're not important elsewhere but yeah. On the point of that point just briefly as I was reading this I was curious about we don't say anything about NSADs which are an interesting parallel to this whole discussion I don't know maybe it's better for the detailed document but I don't know like where Rebecca's at on a once a week aborted NSAD dose in these types of patients yeah I mean in in general based on my understanding of the literature if I'm worried about their cardiovascular risk from a tryptan standpoint then I'm worried about it for NZ also.
Rebecca C. BurchAnd so I I sort of think of them in tandem.
Craig WilliamsYeah it's not untrue and I've cursed DSA but you know it's I'm not I don't have a problem with an A600800 milligram ibuprofen dose once a week these patients and it gets into and Steve can disagree but you know it gets in like chronic and how often then you know but but I've said it is over the counter to your point earlier as well our patients already using those therapies right right right Steve I don't disagree Craig uh I just you know I I I think the point about you know NSADS is that they have their own a set of risks renal risks cardiovascular risk right you know and and I think there's also the issue of the severity of symptoms here.
Steven E. NissenThat's why shared decision making is so important. Because I mean I have patients of mine that have just disabling migraine brain disease that are hard to manage.
Lori DickersonAnd so they have to be treated differently than people that have an occasional true yeah you know Rebecca I want to go back to this wording we're getting some questions about we say for instance consider neuromeds um that don't cause vasoconstriction for patients with multiple cardiovascular risks and so I guess uh the questions are coming in you know were patients with cardiovascular disease included in these clinical trials with the uh the uh ditans and the jepins um like Nertec and RavO can you comment on that yes yeah so those patients were included in those studies and and those uh both all of the new acute treatments have also had dedicated cardiac safety um trials all of which have not shown none of which have shown any issues okay very good and we also have some questions about you know previously we have um you know talked about the word vasoconstriction um with respect to the mechanism of action of tryptans that they uh don't cause vasoconstrict constriction um and they work through serotonin and here in our in our piece about the newer meds we say that these also don't cause vasoconstriction so there's a little bit of uh confusion there and I guess I want to be sure that you're okay with our wording there to say that these newer meds don't cause vasoconstriction.
Lori DickersonAre you good with that wording?
Rebecca C. BurchYeah that is that is the wording that I mean I instead of don't cause it might be fairer to say uh you know are believed not to cause or um you know have not been found or something because you know they could always find out tomorrow that they do.
Lori DickersonWell that's why we were thinking about changing that wording to say haven't yet been linked to cardiovascular events. These these newer agents haven't yet been linked to cardiovascular events and is that misleading or is that more truthful to what we actually know today?
Rebecca C. BurchAs far, I mean I they've looked the there have been many studies of cardiovascular safety um for all CGRP targeted medications because it's one of the sort of um you know predicted side effects of these medications and there has been no signal of um you know cardiovascular um adverse events or risks associated. Okay.
Lori DickersonAnd Greg, do you have any thoughts on that wording about you know the newer meds I you had made a comment or question about them, you know, and their cardiovascular risk. What do you think about our wording here?
Craig WilliamsYeah like everything Rebecca said is true and certainly I think about kind of systemic vasoconstriction versus we're now on this neurogenic origin of, I mean this is clear there's a vascular component to this disease, but it's more locally and neurogenic rather than systemic. And so that is true these newer meds do not cause hypertension and and yeah as yet not linked to cardiovascular events as yet not linked to cardiovascular events.
NarratorWe hope you enjoyed and gained practical insights from listening into this discussion. Now that you've listened you can receive CE credit from Pharmacist Letter just log into your Pharmacist Letter account and look for the title of this podcast in the list of available CE courses. If you're not yet a Pharmacist Letter subscriber, find out more about our product offerings at trchealthcare dot com. Be sure to follow or subscribe, rate and review this show in your favorite podcast app. It helps spread the word about our show and is a great way for you to let us know how we're doing you can also reach out to provide feedback or make suggestions by emailing us at contact us at trchealthcare dot com.
Listen in as our expert panel walks through today’s full range of obesity treatment options - from older agents like orlistat and phentermine/topiramate to the latest GLP-1 therapies - and how to match the right...
A bonus episode from our sister show, Natural Medicines: Evidence in Practice. Weight loss supplements labeled tejocote, Nuez de la India, or Brazil seeds have been found to contain toxic yellow oleander, and as few as...
Poisonings are a significant public health concern - in 2024 alone, U.S. poison centers received over 2 million reported exposures. Listen in as our expert panel of toxicologists and poison-center specialists discusses...
Listen in as our expert panel breaks down what clinicians need to know about the 2026 dyslipidemia guidelines, such as the role of lipoprotein a, apolipoprotein B, and coronary artery calcium scoring. Plus, you'll walk...
Listen in as our expert panel untangles the latest recommendations for using equations to estimate kidney function. You’ll hear their insights on when and how to use creatinine, cystatin C, or both to help safely adjust...